Long-term immunological consequences of anti-CD20 therapies on humoral responses to COVID-19 vaccines in multiple sclerosis: an observational study.

"Conflict of interest statement: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: TM received travel support and honoraria for presentations or participation on advisory boards from Biogen Idec, Celgene, Novartis, Roche, Sanofi, Merck and Teva. FO received travel support and honoraria for presentations or participation on advisory boards from Biogen Idec, Celgene, Novartis, Roche, Sanofi, Merck and Teva. ET has received consultation fees and/or speakers’ honoraria from Arvelle, Argenx, Angelini, Bial, Bio-gen-Idec, Boehringer Ingelheim, Eisai, Epilog, GL Pharma, GW Pharmaceuticals, Ever Pharma, Hikma, LivaNova, Marinus, Medtronics, Newbridge, Novartis, Sanofi, Genzyme, and UCB Pharma. PW received consultation fees and/or speakers’ honoraria from Bayer, Biogen Idec, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi Genzyme, Teva Pharmaceutical Industries Ltd. He received research grants from Biogen Idec and Merck. The remaining authors have no competing interests."

"Funding: The authors received no financial support for the research, authorship, and/or publication of this article."